Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis

Kimberly A. Risma, Robert W. Frayer, Alexandra H. Filipovich, Janos Sumegi

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Missense mutations in perforin, a critical effector of lymphocyte cytotoxicity, lead to a spectrum of diseases, from familial hemophagocytic lymphohistiocytosis to an increased risk of tumorigenesis. Understanding of the impact of mutations has been limited by an inability to express human perforin in vitro. We have shown, for the first time to our knowledge, that recombinant human perforin is expressed, processed appropriately, and functional in rat basophilic leukemia (RBL) cells following retroviral transduction. Subsequently, we have addressed how perforin missense mutations lead to absent perforin detection and impaired cytotoxicity by analyzing 21 missense mutations by flow cytometry, immunohistochemistry, and immunoblot. We identified perforin missense mutations with partial maturation (class 1), no apparent proteolytic maturation (class 2), and no recognizable forms of perforin (class 3). Class 1 mutations exhibit lytic function when expressed in RBL cells and are associated with residual protein detection and variable cytotoxic function in affected individuals, suggesting that carriers of class 1 alleles may exhibit more subtle immune defects. By contrast, class 3 mutations cause severely diminished perforin detection and cytotoxicity, while class 2 mutations have an intermediate phenotype. Thus, the pathologic mechanism of perforin missense mutation likely involves a protein dosage effect of the mature protein.

Original languageEnglish (US)
Pages (from-to)182-192
Number of pages11
JournalJournal of Clinical Investigation
Volume116
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Hemophagocytic Lymphohistiocytosis
Perforin
Missense Mutation
Mutation
Leukemia
Proteins
Flow Cytometry
Carcinogenesis
Immunohistochemistry
Alleles
Lymphocytes
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. / Risma, Kimberly A.; Frayer, Robert W.; Filipovich, Alexandra H.; Sumegi, Janos.

In: Journal of Clinical Investigation, Vol. 116, No. 1, 01.01.2006, p. 182-192.

Research output: Contribution to journalArticle

Risma, Kimberly A. ; Frayer, Robert W. ; Filipovich, Alexandra H. ; Sumegi, Janos. / Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. In: Journal of Clinical Investigation. 2006 ; Vol. 116, No. 1. pp. 182-192.
@article{9df73ac4200849d2a209b7bc30fe19ee,
title = "Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis",
abstract = "Missense mutations in perforin, a critical effector of lymphocyte cytotoxicity, lead to a spectrum of diseases, from familial hemophagocytic lymphohistiocytosis to an increased risk of tumorigenesis. Understanding of the impact of mutations has been limited by an inability to express human perforin in vitro. We have shown, for the first time to our knowledge, that recombinant human perforin is expressed, processed appropriately, and functional in rat basophilic leukemia (RBL) cells following retroviral transduction. Subsequently, we have addressed how perforin missense mutations lead to absent perforin detection and impaired cytotoxicity by analyzing 21 missense mutations by flow cytometry, immunohistochemistry, and immunoblot. We identified perforin missense mutations with partial maturation (class 1), no apparent proteolytic maturation (class 2), and no recognizable forms of perforin (class 3). Class 1 mutations exhibit lytic function when expressed in RBL cells and are associated with residual protein detection and variable cytotoxic function in affected individuals, suggesting that carriers of class 1 alleles may exhibit more subtle immune defects. By contrast, class 3 mutations cause severely diminished perforin detection and cytotoxicity, while class 2 mutations have an intermediate phenotype. Thus, the pathologic mechanism of perforin missense mutation likely involves a protein dosage effect of the mature protein.",
author = "Risma, {Kimberly A.} and Frayer, {Robert W.} and Filipovich, {Alexandra H.} and Janos Sumegi",
year = "2006",
month = "1",
day = "1",
doi = "10.1172/JCI26217",
language = "English (US)",
volume = "116",
pages = "182--192",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis

AU - Risma, Kimberly A.

AU - Frayer, Robert W.

AU - Filipovich, Alexandra H.

AU - Sumegi, Janos

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Missense mutations in perforin, a critical effector of lymphocyte cytotoxicity, lead to a spectrum of diseases, from familial hemophagocytic lymphohistiocytosis to an increased risk of tumorigenesis. Understanding of the impact of mutations has been limited by an inability to express human perforin in vitro. We have shown, for the first time to our knowledge, that recombinant human perforin is expressed, processed appropriately, and functional in rat basophilic leukemia (RBL) cells following retroviral transduction. Subsequently, we have addressed how perforin missense mutations lead to absent perforin detection and impaired cytotoxicity by analyzing 21 missense mutations by flow cytometry, immunohistochemistry, and immunoblot. We identified perforin missense mutations with partial maturation (class 1), no apparent proteolytic maturation (class 2), and no recognizable forms of perforin (class 3). Class 1 mutations exhibit lytic function when expressed in RBL cells and are associated with residual protein detection and variable cytotoxic function in affected individuals, suggesting that carriers of class 1 alleles may exhibit more subtle immune defects. By contrast, class 3 mutations cause severely diminished perforin detection and cytotoxicity, while class 2 mutations have an intermediate phenotype. Thus, the pathologic mechanism of perforin missense mutation likely involves a protein dosage effect of the mature protein.

AB - Missense mutations in perforin, a critical effector of lymphocyte cytotoxicity, lead to a spectrum of diseases, from familial hemophagocytic lymphohistiocytosis to an increased risk of tumorigenesis. Understanding of the impact of mutations has been limited by an inability to express human perforin in vitro. We have shown, for the first time to our knowledge, that recombinant human perforin is expressed, processed appropriately, and functional in rat basophilic leukemia (RBL) cells following retroviral transduction. Subsequently, we have addressed how perforin missense mutations lead to absent perforin detection and impaired cytotoxicity by analyzing 21 missense mutations by flow cytometry, immunohistochemistry, and immunoblot. We identified perforin missense mutations with partial maturation (class 1), no apparent proteolytic maturation (class 2), and no recognizable forms of perforin (class 3). Class 1 mutations exhibit lytic function when expressed in RBL cells and are associated with residual protein detection and variable cytotoxic function in affected individuals, suggesting that carriers of class 1 alleles may exhibit more subtle immune defects. By contrast, class 3 mutations cause severely diminished perforin detection and cytotoxicity, while class 2 mutations have an intermediate phenotype. Thus, the pathologic mechanism of perforin missense mutation likely involves a protein dosage effect of the mature protein.

UR - http://www.scopus.com/inward/record.url?scp=31044453814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31044453814&partnerID=8YFLogxK

U2 - 10.1172/JCI26217

DO - 10.1172/JCI26217

M3 - Article

C2 - 16374518

AN - SCOPUS:31044453814

VL - 116

SP - 182

EP - 192

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -